Table of Contents
Gonorrhea is a common sexually transmitted infection caused by the bacterium Neisseria gonorrhoeae. It can infect the genitourinary tract, rectum, and throat. Effective treatment is essential to prevent complications and curb transmission.
Historical Role of Fluoroquinolones in Gonorrhea Treatment
Fluoroquinolones, such as ciprofloxacin and ofloxacin, were once mainstays in treating gonorrhea due to their broad-spectrum activity and oral administration. They offered a convenient alternative to injectable therapies like ceftriaxone.
Decline in Use Due to Resistance
Over time, Neisseria gonorrhoeae developed resistance to fluoroquinolones, leading to decreased effectiveness. Surveillance reports indicated rising resistance rates, prompting updates in treatment guidelines.
Current Recommendations for Pharmacists
Today, fluoroquinolones are no longer recommended for gonorrhea treatment in most regions. The Centers for Disease Control and Prevention (CDC) and other health authorities advise against their use due to resistance concerns.
Alternative Treatment Options
- Ceftriaxone 500 mg intramuscularly in a single dose
- Cefixime 800 mg orally in a single dose (if ceftriaxone is unavailable)
- Combination therapy with azithromycin or doxycycline, depending on local resistance patterns
Implications for Pharmacists
Pharmacists should stay informed about evolving treatment guidelines and resistance patterns. They play a key role in patient education, ensuring adherence, and preventing the spread of resistant strains.
Future Directions
Research continues into new antibiotics and combination therapies to combat resistant N. gonorrhoeae. Surveillance and stewardship are critical to preserving the efficacy of existing treatments.